-
公开(公告)号：US20190322744A1
公开(公告)日：2019-10-24
申请号：US16448016
申请日：2019-06-21
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE SOULAS , NICOLAI WAGTMANN
IPC: C07K16/28
Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
-
公开(公告)号：US20170291947A1
公开(公告)日：2017-10-12
申请号：US15511778
申请日：2015-09-15
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , NICOLAI WAGTMANN
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
-
3.发明申请公开(公告)号：US20200369764A1
公开(公告)日：2020-11-26
申请号：US16629585
申请日：2018-07-09
Applicant: INNATE PHARMA
Inventor： STÉPHANIE CORNEN , BENJAMIN ROSSI , NICOLAI WAGTMANN
Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
-
公开(公告)号：US20190031755A1
公开(公告)日：2019-01-31
申请号：US16071499
申请日：2017-01-20
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE DENIS , CARINE PATUREL , NICOLAI WAGTMANN
Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
-
公开(公告)号：US20170306014A1
公开(公告)日：2017-10-26
申请号：US15509859
申请日：2015-09-09
Applicant: INNATE PHARMA
Inventor： STÉPHANIE CORNEN , BENJAMIN ROSSI , NICOLAI WAGTMANN
IPC: C07K16/28 , C07K16/30 , A61K39/395
CPC classification number: C07K16/2803 , A61K39/395 , C07K16/28 , C07K16/30 , C07K2317/33 , C07K2317/73 , C07K2317/76
Abstract: This invention relates to agents that bind multiple Siglecs, including antibodies that neutralize the inhibitory activity of multiple Siglec-7 and Siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease.
-
Patent Agency Ranking
公开(公告)号：US20230303691A1
公开(公告)日：2023-09-28
申请号：US18331966
申请日：2023-06-09
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE DENIS , CARINE PATUREL , NICOLAI WAGTMANN
CPC classification number: C07K16/2803 , C07K16/2818 , A61P35/00 , A61K2039/507
Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
-
公开(公告)号：US20200369765A1
公开(公告)日：2020-11-26
申请号：US16629588
申请日：2018-07-09
Applicant: INNATE PHARMA
Inventor： STÉPHANIE CORNEN , BENJAMIN ROSSI , NICOLAI WAGTMANN , LAURENT GAUTHIER
IPC: C07K16/28
Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
-
公开(公告)号：US20170313773A1
公开(公告)日：2017-11-02
申请号：US15521401
申请日：2015-10-23
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE SOULAS , NICOLAI WAGTMANN
CPC classification number: C07K16/2803 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2863 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure relates to HLA-E as a tumor escape mechanism in head and neck cancer. The disclosure relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
-
公开(公告)号：US20210122821A1
公开(公告)日：2021-04-29
申请号：US17128241
申请日：2020-12-21
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE DENIS , CARINE PATUREL , NICOLAI WAGTMANN
Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.
-
公开(公告)号：US20200332008A1
公开(公告)日：2020-10-22
申请号：US16924288
申请日：2020-07-09
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , NICOLAI WAGTMANN
IPC: C07K16/28 , A61K39/395 , C07K16/30
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.014 seconds)
